**Specifications table**TableSubject area*Chemistry, Pharmacy*More specific subject area*Hydrolysis mechanism of polymeric nanocapsules*Type of data*Tables, images and figures*How data was acquired*SEC by GPCMax tripledetector (Viscotek, Malvern Instruments Ltd, England, UK, columns of Styragel 10*^*4*^*, 10*^*5*^*, and 10*^*6*^* Å), laser diffraction (Malvern Mastersizer® 2000, Malvern Instruments, UK), dynamic light scattering (DLS, Malvern Zetasizer instrument - NanoZS, Malvern Instruments, UK) and absorbance values were measured by spectrometry (Spectramax M2e -- SoftMax Pro Software Interface 5) at 370 nm.*Data format*Raw, analyzed*Experimental factors*SEC analyses were performed after extraction procedure of all constituents of LNC and separation of precipitate (polymer) and supernatant (lower molar mass constituents).Microscopy images, turbidimetry and diameter analyses of LNC were obtained without pre-treatment of samples.*Experimental features*Details of experimental methodologies used in this study such as preparation of nanoemulsion and nanosphere formulations. Sterilization process of LNC formulations and the efficacy of this technique by microbiological analyses. Characterization of LNC formulations after storage by SEC to identify the predominant hydrolysis mechanism. Particle size analyses to characterize physicochemical stability.*Data source location*Porto Alegre, Brazil*Data accessibility*Data is provided with this article*Related research article[@bib1] S. Calgaroto, L. E. Fauri, L. Frank, K. Paese, S. S. Guterres, A. R. Pohlmann, Chemical stability, mass loss and hydrolysis mechanism of sterile and non-sterile lipid-core nanocapsules: the influence of the molar mass of the polymer wall, *Reactive and Functional Polymers, 2018*

**Value of the data**•*SEC molar mass profiles of all the material constituents of polymeric nanocapsules is innovative for the scientific community since for most of the investigations just the polymer wall is evaluated for complex colloidal systems.*•*Microbiological analyses of sterile and non-sterile LNC formulations provided information on the efficiency of the sterilization process and were are useful for their evaluation.*•*Laser diffraction and dynamic light scattering (DLS) were compared with data from other works when analyzed the storage of similar delivery system and prove that physical parameters does not suffer alteration during the storage.*

1. Data {#s0005}
=======

The data presented in Section 1.1 is the initial physicochemical characterization of LNC formulations, prior and after sterilization process. The size distribution profiles of formulations are showed in [Fig. 1](#f0005){ref-type="fig"} and the DLS profile in [Fig. 2](#f0010){ref-type="fig"}. Section 1.2 involves the determination of each LNC constituent material by size exclusion chromatography (SEC) ([Fig. 3](#f0015){ref-type="fig"}). The data presented in Section 1.3 includes the determination of crystallinity degree for the LNC constituents and LNC formulations, prior and after sterilization process ([Table 1](#t0005){ref-type="table"}). Section 1.4 brings data referent to sterilization process and microbiological analyses that prove their efficacy ([Table 2](#t0010){ref-type="table"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). The data containing in Section 1.5 is related to the SEC profiles and molecular weight changes for the LNC constituents, prior and after sterilization ([Fig. 6](#f0030){ref-type="fig"} and [Table 3](#t0015){ref-type="table"}). Section 1.6 show data referent to physicochemical characterization for nanocapsules formulations, non-sterile (LNC) and sterile (LNCS), storage at 5 °C (60 days) by laser diffraction ([Fig. 7](#f0035){ref-type="fig"}) and DLS analyses ([Table 4](#t0020){ref-type="table"}). Section 1.7 presented the changes on molar mass of nanocapsules formulations (precipitate -- [Fig. 8](#f0040){ref-type="fig"} and supernatant -- [Fig. 9](#f0045){ref-type="fig"}) storage at 5 °C (60 days). The statistical analyses applied in all SEC results are presented in the same section ([Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}).Fig. 1Size distribution profiles by laser diffraction of nanocapsule formulations: before (LNC) and after (LNCS) sterilization process. The data are expressed by volume of particles (left) and by number of particles (right).Fig. 1Fig. 2Size distribution profiles by DLS analysis of nanocapsule formulations: before (LNC) and after (LNCS) sterilization process, expressed by intensity (%). Inset: self-correlation function coefficient - G(τ) versus decay time - (μs), has been computed by applying the CONTIN method.Fig. 2Fig. 3Curves of molecular weight distribution of each LNC constituent material, obtained by size exclusion chromatography (SEC).Fig. 3Table 1Degree of crystallinity (%) of formulations, before (LNC) and after (LNCS) sterilization process and of the PCL with different molar masses by XRD.Table 1Sample/materialDegree of crystallinity (%)LNC 165.9LNCS 165.6LNC 259.2LNCS 259.6LNC 362.8LNCS 363.4PCL 183.1PCL 278.9PCL 364.1[^1]Table 2Absorbance values of the formulations after 48 h of incubation with LB Medium (λ = 370 nm). Values represent mean ± standard deviation (n=3).Table 2**Formulation1μL mL**^**-1**^**5μL mL**^**-1**^**10μL mL**^**-1**^Incubated LNCS 10.18 ± 0.010.33 ± 0.000.56 ± 0.01Control LNCS 10.19 ± 0.010.34 ± 0.020.56 ± 0.01Incubated LNCS 20.21 ± 0.000.62 ± 0.020.80 ± 0.02Control LNCS 20.24 ± 0.010.65 ± 0.010.80 ± 0.02Incubated LNCS 30.24 ± 0.000.65 ± 0.020.83 ± 0.02Control LNCS 30.23 ± 0.010.63 ± 0.020.87 ± 0.01Incubated LNC 10.80 ± 0.04[\*](#tbl2fnStar){ref-type="table-fn"}0.88 ± 0.01[\*](#tbl2fnStar){ref-type="table-fn"}0.93 ± 0.01[\*](#tbl2fnStar){ref-type="table-fn"}Control LNC 10.22 ± 0.010.36 ± 0.010.57 ± 0.02Incubated LNC 20.35 ± 0.02[\*](#tbl2fnStar){ref-type="table-fn"}0.72 ± 0.01[\*](#tbl2fnStar){ref-type="table-fn"}0.92 ± 0.01[\*](#tbl2fnStar){ref-type="table-fn"}Control LNC 20.32 ± 0.010.68 ± 0.010.86 ± 0.01Incubated LNC 30.36 ± 0.02[\*](#tbl2fnStar){ref-type="table-fn"}0.75 ± 0.01[\*](#tbl2fnStar){ref-type="table-fn"}0.94 ± 0.01[\*](#tbl2fnStar){ref-type="table-fn"}Control LNC 30.32 ± 0.020.69 ± 0.020.89 ± 0.01[^2]Fig. 4Inoculation of the non-sterile LNC 1 (a), LNC 2(c) and LNC 3 (e) and sterile formulations LNCS 1(b), LNCS 2 (d) and LNCS 3 (f) in a blood agar plate during 48 h at 37 ± 1 °C.Fig. 4Fig. 5Inoculation of the non-sterile LNC 1 (a), LNC 2(c) and LNC 3 (e) and sterile formulations LNCS 1(b), LNCS 2 (d) and LNCS 3 (f) in a *Sabouraud* plate during 48 h at 35 ± 1 °C.Fig. 5Fig. 6Molecular weight distribution profiles for LNCs, before (LNC) and after sterilization (LNCS): (a) precipitate and (b) supernatant, obtained by size exclusion chromatography (SEC). In (a), peaks (1), (2) and (3) are equivalent to the molecular weight of CCT, MS + P80 and PCL, respectively.Fig. 6Table 3Retention Volume (mL), number average molecular weight (*M*~*n*~), molecular weight (*M*~*w*~) and dispersity (Đ = *Mw/Mn*) of LNC (supernatant), before and after sterilization process, by size exclusion chromatography (SEC).Table 3SamplePeaks by SECRetention volume (mL)*M*~*n*~*M*~*w*~Dispersity (Đ = *M*~*w*~/*M*~*n*~)LNC 1(1)38.094906611.10(2)37.28202017791.08LNCS 1(1)38.095746311.16(2)37.28168518431.09LNC 2(1)38.096577231.10(2)37.28165318321.11LNCS 2(1)38.096887251.05(2)37.28171019301,13LNC 3(1)38.116789051.33(2)36.50169020001.18LNCS 3(1)38.116569021.37(2)36.50174019801.14[^3]Fig. 7Radar charts plot for nanocapsules formulations, non-sterile (LNC) and sterile (LNCS), storage at 5 °C (60 days). \[axes: 1 - volume-weighted mean diameter by volume of particles, d\[3,4\]v; 2 - diameter by volume at percentile 10 under the distribution curve, d(0.1)v; 3 - diameter by volume at percentile 50 under the distribution curve, d(0.5)v; 4 - diameter by volume at percentile 90 under the distribution curve, d(0.9)v; 5 - volume-weighted mean diameter by number of particles, d\[3,4\]n; 6 - diameter by number at percentile 10 under the distribution curve, d(0.1)n; 7 - diameter by number at percentile 50 under the distribution curve, d(0.5)n; 8 - diameter by number at percentile 90 under the distribution curve, d(0.9)n\].Fig. 7Table 4*z*-Average diameters and polydispersity (PDI) determined by dynamic light scattering (DLS) for formulations before and after the storage time (60 days) (semi-dilute regimen).Table 4FormulationStorage time (days)PCS (Method of Cumulants)*z-average* diameters (nm)PDI (dimensionless)LNC 10198 ± 100.10 ± 0.0360213 ± 40.11 ± 0.02LNCS 10200± 30.11 ± 0.0460205± 160.10 ± 0.03LNC 20207 ± 90.10 ± 0.0360211 ± 30.11 ± 0.01LNCS 20202 ± 50.13 ± 0.0160218 ± 20.13 ± 0.03LNC 30202 ± 90.12 ± 0.0160211 ± 140.11 ± 0.02LNCS 30185 ± 20.09 ± 0.0060184 ± 30.10 ± 0.01[^4]Fig. 8Molecular weight distribution profiles for nanocapsule formulations (precipitate), storage at 5 °C (60 days). Results obtained by size exclusion chromatography (SEC). LNC - non-sterile; LNCS -- sterile. Peaks (1), (2) and (3) are equivalent to the molecular weight of CCT, MS + P80 and PCL, respectively.Fig. 8Fig. 9Molecular weight distribution profiles for nanocapsule formulations (supernatant) - LNC - non-sterile; LNCS -- sterile, storage at 5 °C (60 days). Results obtained by size exclusion chromatography (SEC).Fig. 9Table 5Statistical analysis of the weight loss \[∆*M*~*w*~ (%)\] and dispersity (Đ = *M*~*w*~*/M*~*n*~) for the non-sterile and sterile nanocapsule formulations (precipitate) under storage, at 5 °C, by SEC. Peaks (1), (2) and (3) are equivalent to the molecular weight of CCT, MS + P80 and PCL, respectively.Table 5Storage (days)Peak (SEC)Weight loss (∆*M*~*w*~ %)Dispersity (Đ = *M*~*w*~/*M*~*n*~)LNC 1LNCS 1LNC 2LNCS 2LNC 3LNCS 3LNC 1LNCS 1LNC 2LNCS 2LNC 3LNCS 30(1)^A^0^aA^0^aA^0^aA^0^aA^0^aA^0^aA^1.20^aA^1.17^aA^1.18^aA^1.27^aA^1.08^aA^1.08^a^(2)^A^0^aA^0^aA^0^aA^0^aA^0^aA^0^aA^1.17^aA^1.17^aA^1.23^aA^1.26^aA^1.22^aA^1.22^a^(3)^A^0^aA^0^aA^0^aA^0^aA^0^aA^0^aA^1.47^aA^1.47^aA^2.29^aA^2.28^aA^2.25^aA^2.27^a^10(1)^A^0^aA^0^aA^1.2^aA^1.5^aA^1.4^aA^2.5^aA^1.17^aA^1.18^aA^1.19^aA^1.21^aA^1.07^aA^1.22^b^(2)^A^0^aA^0^aA^0.8^aA^0.9^aA^7.6^aA^8.5^aA^1.16^aA^1.20^aA^1.20^aA^1.20^aA^1.15^aA^1.18^a^(3)^A^0^aA^0^aA^13.6^bB^3.5^aA^16.0^bB^5.0^aA^1.54^aA^1.52^aA^2.21^bA^2.29^aA^2.18^aA^2.27^a^15(1)^A^7.4^aA^0.2^aA^3.9^aA^4.4^aA^14.1^bB^2.4^aA^1.27^aB^1.16^aA^1.20^aA^1.20^aA^1.12^aA^1.10^a^(2)^A^0^aA^0^aA^6.5^aA^8.1^aA^6.5^aA^7.1^aA^1.17^aA^1.23^aA^1.21^aA^1.15^aA^1.16^aA^1.16^a^(3)^A^3.8^aA^3.2^aA^13.8^bB^2.8^aA^17.2^bB^8.2^aA^1.58^aA^1.51^aA^2.37^bA^2.31^aA^2.15^aA^2.25^a^30(1)^A^40.7^bB^18.4^bA^46.7^bB^18.2^bA^18.6^bB^5.1^aA^1.13^aA^1.10^aA^1.41^bB^1.15^aA^1.23^bA^1.15^a^(2)^A^41.4^bB^1.3^aA^35.1^bB^14.9^bA^4.1^aA^5.2^aA^1.12^aA^1.15^aA^1.29^aB^1.40^bA^1.16^aA^1.11^b^(3)^A^29.3^bB^18.3^bA^28.5^cB^15.0^bA^24.3^bB^12.5^bA^1.78^bB^1.50^aA^2.46^bB^2.29^aA^2.07^bB^2.23^a^60(1)^A^54.2^cB^21.3^cA^50.0^bB^33.8^cA^20.4^bB^1.0^aA^1.33^bA^1.35^bA^1.61^bB^1.35^bA^1.23^bA^1.27^b^(2)^A^46.1^bB^13.7^bA^35.7^bB^25.5^cA^6.9^aA^7.9^aA^1.05^aB^1.20^aA^1.32^bA^1.35^bA^1.13^bA^1.13^b^(3)^A^43.0^cB^28.9^cA^31.7^cB^19.8^bA^28.4^bB^18.2^bA^1.55^aA^1.52^aA^2.47^bA^2.41^bA^2.01^bB^2.14^b^[^5][^6][^7]Table 6Statistical analysis of the number average molecular weight (*M*~*n*~) and molecular weight (*M*~*w*~) for the non-sterile and sterile nanocapsule formulations (precipitate), under storage, at 5 °C, by SEC. Peaks (1), (2) and (3) are equivalent to the molecular weight of CCT, MS + P80 and PCL, respectively.Table 6Storage (days)Peak (SEC)*M*~*n*~*M*~*w*~LNC 1LNCS 1LNC 2LNCS 2LNC 3LNCS 3LNC 1LNCS 1LNC 2LNCS 2LNC 3LNCS 30(1)^A^1024^aA^1,031^aA^1047^aA^1045^aA^652^aA^655^aA^1228^aA^1203^aA^1231^aA^1320^aA^706^aA^710^a^(2)^A^2777^aA^2799^aA^3010^aA^3065^aA^1799^aA^1798^aA^3240^aA^3280^aA^3703^aA^3870^aA^2187^aA^2193^a^(3)^A^32,987^aA^32,478^aA^75,300^aA^75,658^aA^71,000^aA^70,200^aA^48,475^aA^47,778^aA^173,681^aA^185,076^aA^159,790^aA^159,300^a^10(1)^A^1019^aA^1,014^aA^1024^aA^1045^aA^649^aA^579^aA^1195^aA^1200^aA^1216^aA^1265^aA^695^aA^680^a^(2)^A^2769^aA^2798^aA^3015^aA^3042^aA^1757^aA^1750^aA^3220^aA^3300^aA^3646^aA^3670^aA^2020^aA^2075^a^(3)^A^31,377^aA^31,338^aA^69,600^aA^75,505^aA^60,900^bA^67,000^bA^48,400^aA^47,545^aA^161,379^bB^178,330^aA^132,875^bB^152,280^a^15(1)^A^896^bB^1,026^aA^990^bA^1044^aA^542^bA^624^aA^1138^aA^1200^aA^1185^aA^1257^aA^605^bA^689^a^(2)^A^2760^aA^2795^aA^2887^aA^3033^aA^1764^aA^1748^aA^3238^aA^3500^aA^3489^aA^3411^aA^2044^aA^2031^a^(3)^A^29,453^aA^30,590^aA^67,030^bB^75,515^aA^60,213^bA^65,000^bA^46,615^aA^46,550^aA^161,000^bB^180,280^aA^129,600^bB^146,178^a^30(1)^A^647^b,cB^907^bA^463^cB^955^aA^467^bA^585^aA^729^bB^983^bA^655^bB^1080^aA^575^bA^672^a^(2)^A^1687^bB^2082^bA^1860^bB^2400^bA^1820^aA^1940^aA^1898^bB^3240^aA^2405^bB^3290^aA^2105^aA^2145^a^(3)^A^19,278^bB^25,935^bA^54,300^cB^68,550^bA^57,952^bA^62,490^bA^34,068^bB^38,995^bA^133,608^cB^157,300^bA^119,870^cB^139,350^a^60(1)^A^427^cB^573^bA^386^cB^617^bA^467^bA^553^aA^562^cB^946^bA^615^bB^835^bA^573^bB^700^a^(2)^A^1659^bB^2010^bA^1838^bA^2020^bA^1765^aA^1839^aA^1748^bB^2830^bA^2380^bA^2729^bA^2000^aA^2085^a^(3)^A^18,140^bB^22,450^bA^52,415^cB^59,350^bA^56,850^bA^61,000^bA^27,615^cB^33,975^bA^127,500^cB^143,000^bA^114,500^cB^130,500^b^[^8][^9][^10]Table 7Statistical analysis of the number average molecular weight (*M*~*n*~) and molecular weight (*M*~*w*~) for the non-sterile and sterile nanocapsule formulations (supernatant), under storage, at 5 °C, by SEC.Table 7Storage (days)*M*~*n*~*M*~*w*~LNC 1LNCS 1LNC 2LNCS 2LNC 3LNCS 3LNC 1LNCS 1LNC 2LNCS 2LNC 3LNCS 30^A^236^aA^244^aA^320^aA^320^aA^325^aA^295^aA^1027^aA^1020^aA^1126^aA^1199^aA^1087^aA^1030^a^10^A^268^aA^235^aA^269^aA^287^aA^264^aA^283^aA^996^aA^997^aA^1047^aA^1126^aA^983^aA^944^a^15^A^310^aA^270^aA^370^aA^290^aA^262^aA^255^aA^1025^aA^1016^aA^1059^aA^1128^aA^976^aA^949^a^30^A^264^aA^277^aA^270^aA^266^aA^252^aA^264^aA^897^bA^929^aA^1087^aA^1135^aA^923^aA^882^b^60^A^126^bA^125^bA^135^bA^146^bA^173^bA^175^bA^430^cA^420^bA^450^bA^491^bA^684^bB^773^b^[^11][^12][^13]

1.1. Initial physicochemical characterization of LNC formulations, prior and after sterilization process {#s0010}
--------------------------------------------------------------------------------------------------------

 See [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}.

1.2. Size exclusion chromatography (SEC) analysis of each LNC constituent material {#s0015}
----------------------------------------------------------------------------------

 See [Fig. 3](#f0015){ref-type="fig"}.

1.3. Crystallinity measurement for the LNC constituents and LNC formulations, prior and after sterilization process {#s0020}
-------------------------------------------------------------------------------------------------------------------

 See [Table 1](#t0005){ref-type="table"}.

1.4. Microbiological contamination assays {#s0025}
-----------------------------------------

### 1.4.1. Turbidimetry test {#s0030}

 See [Table 2](#t0010){ref-type="table"}.

### 1.4.2. Fungi and bacteria detection {#s0035}

 See [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}.

1.5. Molecular weight changes for the LNC constituents, prior and after sterilization process {#s0040}
---------------------------------------------------------------------------------------------

 See [Fig. 6](#f0030){ref-type="fig"} and [Table 3](#t0015){ref-type="table"}.

1.6. Physicochemical characterization for nanocapsule formulations, non-sterile (LNC) and sterile (LNCS), storage at 5 °C (60 days) {#s0045}
-----------------------------------------------------------------------------------------------------------------------------------

### 1.6.1. Particle size analyses by laser diffraction -- radar charts {#s0050}

 See [Fig. 7](#f0035){ref-type="fig"} and [Table 4](#t0020){ref-type="table"}.

1.7. Molecular weight distribution profiles for nanocapsules formulations (precipitate and supernatant) storage at 5 °C (60 days) {#s0055}
---------------------------------------------------------------------------------------------------------------------------------

 See [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}; [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}.

2. Experimental design, materials and methods {#s0060}
=============================================

The methodologies to obtain the data exposed here are described in Calgaroto et al. [@bib1].

2.1. Preparation of Nanoemulsion (NE) and Nanosphere (NS) formulations {#s0065}
----------------------------------------------------------------------

To prepare NE formulation, an organic phase containing 0.038 g of sorbitan monostearate, 0.160 g of oil (capric/caprylic triglyceride) and 27 mL acetone was injected into an aqueous phase containing 0.080 g polysorbate 80 and 53 mL ultrapure water, under magnetic stirring at 40 °C. To prepare NS, the organic phase was composed by 0.100 g poly(ε-caprolactone), 0.038 g of sorbitan monostearate solubilized in 27 mL acetone. This phase was injected into an aqueous phase containing 0.080 g polysorbate 80 and 53 mL ultrapure water, under magnetic stirring at 40 °C. For both formulations, after 10 min, the organic solvent was removed under reduced pressure at 40 °C using a rotary evaporator (Büchi, Switzerland), having their volume reduced to 10 mL. The formulations prepared in triplicate batches (n = 3).

2.2. Sterilization process {#s0070}
--------------------------

Sterilization was performed in Horizontal Autoclave (Phoenix AB42, São Paulo, Brazil) at 134 °C for 10 min and 2.10 bar as previously described [@bib2]. Initially, 5 mL of each formulation was packed in ampoule bottles (h = 100 mm; ᴓ = 5 mm; v = 10 mL) using a micropipette (\#BR704764) (BRAND® Transferpette® S pipette, single channel) acquired from Sigma-Aldrich (Steinheim, Germany). This container were sealed with rubber stoppers and aluminum seals with the aid of a climper (\#224321) purchased from SKS Science Products (Watervliet, New York). The ampoule bottles, rubber stoppers and aluminum seals were purchase from Galia Embalagens (Porto Alegre, Brazil). After sterilization, the formulations were immediately removed from the autoclave and kept at 5 °C in a refrigerator (model: CRM33, Consul®, Brazil), under light.

2.3. Particle size analyses {#s0075}
---------------------------

The nanocapsule formulations were evaluated (particle size distribution) by laser diffraction (LD) using a Malvern Mastersizer® 2000 instrument (Malvern Instruments, UK). The sample (n=3) was placed in the equipment using a micropipette (\#Z646598) (BRAND® Transferpette® S pipette, single channel) acquired from Sigma-Aldrich (Steinheim, Germany) device wet unit (Hydro 2000SM -- AWM2002 -- Malvern, UK) in an amount sufficient to obtain more than 2% obscuration. Mie theory of light scattering was used to calculate the particle size distribution. Mean diameter was expressed as volume-weighted mean diameter (d4,3), and polydispersity (Span) was calculated using Eq. [(1)](#eq0005){ref-type="disp-formula"}, where d0.9, d0.1, and d0.5 are respectively the diameters at percentiles 90, 10, and 50 of the cumulative size distribution curve. The median diameter by number of particles (d0.5)n was also determined for each sample using the distribution curve based on the number of particles.$$\mathit{Span} = \left( \frac{d_{0.9} - d_{0.1}}{d_{0.5}} \right)$$

Dynamic light scattering (DLS) was carried out to determine the mean hydrodynamic diameter and the polydispersity of the submicrometric particle populations in a Nanoseries® ZetaSizer ZS (Malvern, UK) equipment. LNC formulations (20 μL) were diluted in MilliQ® water (10 mL) previously filtered (0.45 μm, hydrophilic membrane (\#HVLP) (Durapore®, Merck, Germany). Each sample was poured into a quartz flow cell (\#ZEN0023, Malvern, UK). The scattered light was detected at an angle of 173°. The correlograms were fit using the method of Cumulants to calculate the z-average diameters. Experiments were conducted with three batches for each sample.

3. Microbiological contamination assays {#s0080}
=======================================

3.1. Turbidimetry test {#s0085}
----------------------

The microbiological contamination was evaluated by a turbidimetry method to identify the presence of microorganisms in the formulation prior (LNC) and after sterilization process (LNCS). The presence of contaminants in the sample is related with the increase in absorbance [@bib3]. The absorbance of formulations without incubation (LNC and LNCS) was determined as the controls. The formulations (LNC and LNCS) were incubated at 37 ± 1 °C during 48 h using three different concentrations by adding 1, 5 or 10 μL of each sample into 1 mL of Luria Bertani (LB) medium. The experiments were performed in triplicate, and the absorbance values were measured by spectrometry (Spectramax M2e -- SoftMax Pro Software Interface 5) at 370 nm.

3.2. Fungi and bacteria detection {#s0090}
---------------------------------

The detection of fungi and bacteria in the formulations was performed by inoculating 20 μL of each formulation (LNC and LNCS) for 48 h at 37 ± 1 and 35 ± 1 °C, respectively, a blood agar plate for the bacterial growing and in a *Sabouraud* plate for the fungal growing.

Transparency document. Supplementary material {#s0061}
=============================================
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[^1]: PCL 1 = *M*~*n*~ 10 kg mol^-1^; PCL 2 = mixture (1:9, w/w) of PCL *M*~*n*~ 10 kg mol^-1^ and *M*~*n*~ 80 kg mol^-1^, respectively; PCL 3 = *M*~*n*~ 80 kg mol^-1^

[^2]: Significantly different p\<0.05 compared to the respective control by the Tukey *post-hoc* test.

[^3]: Values represent mean ± standard deviation (n = 3) \*significantly different p\<0.05 (Analysis of variance (ANOVA), followed by the Tukey *post-hoc* test). Analysis performed comparing each peak, before and after sterilization process.

[^4]: Values represent mean ± standard deviation (n = 3) \*significantly different p\<0.05 (Analysis of variance (ANOVA), followed by the Tukey *post-hoc* test). Analysis performed comparing each sample, before and after 60 days of storage time.

[^5]: ^a,b,c^ analysis performed by row between the different storage times for each independent formulation;

[^6]: ^A,B^ analysis performed by lines comparing the \"sterile and non-sterile\" condition for each storage time;

[^7]: Equivalent letters means statistical equivalence (p \>0.05). Bonferroni׳s test was used as post test. Values are expressed as average (n=3).

[^8]: ^a,b,c^ analysis performed by row between the different storage times for each peak of the each independent formulation;

[^9]: ^A,B^ analysis performed by lines comparing the \"sterile and non-sterile\" condition for each storage time;

[^10]: Equivalent letters means statistical equivalence (p \>0.05). Bonferroni׳s test was used as post test. Values are expressed as average (n=3).

[^11]: ^a,b,c^ analysis performed by row between the different storage times for each independent formulation;

[^12]: ^A,B^ analysis performed by lines comparing the \"sterile and non-sterile\" condition for each storage time;

[^13]: Equivalent letters means statistical equivalence (p\>0.05). Bonferroni׳s test was used as post test. Values are expressed as average (n=3).
